Advair Diskus 500/50 is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is protected by 2 US drug patents filed in 2013 out of which all have expired. Based on its patents and exclusivities, its generic launch date is estimated to be Dec 20, 2020. Details of Advair Diskus 500/50's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
|
US5873360 (Pediatric) | Inhalation device |
Aug, 2016
(8 years ago) |
Expired
|
| US5873360 | Inhalation device |
Feb, 2016
(8 years ago) |
Expired
|
FDA has granted several exclusivities to Advair Diskus 500/50. Till the time these exclusivities are active, no other company can market a generic or bioequivalent version of Advair Diskus 500/50, regardless of the status of it's patents. These exclusivities hence play a crucial role in delaying the generic launch. Given below are details of the exclusivities granted to Advair Diskus 500/50.
Exclusivity Information
Advair Diskus 500/50 holds 2 exclusivities. All of its exclusivities have expired in 2020. Details of Advair Diskus 500/50's exclusivity codes and their expiration dates are given below.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| M(M-84) | Mar 31, 2012 |
| M(M-214) | Dec 20, 2020 |
US patents provide insights into the exclusivity only within the United States, but Advair Diskus 500/50 is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Advair Diskus 500/50's family patents as well as insights into ongoing legal events on those patents.
Advair Diskus 500/50's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Advair Diskus 500/50's generic launch date based on the last expiry date of its patents and exclusivities combined is estimated to be Dec 20, 2020 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Advair Diskus 500/50 Generic API suppliers:
Fluticasone Propionate; Salmeterol Xinafoate is the generic name for the brand Advair Diskus 500/50. 3 different companies have already filed for the generic of Advair Diskus 500/50, with Hikma having the maximum number of approved applications. Check out the entire list of companies who have already received approval for Advair Diskus 500/50's generic
Alternative Brands for Advair Diskus 500/50
Advair Diskus 500/50 which is used for managing symptoms associated with a specific medical condition., has several other brand drugs using the same active ingredient (Fluticasone Propionate; Salmeterol Xinafoate). Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |||
|---|---|---|---|---|
| Glaxo Grp Ltd |
| |||
| Teva Pharm |
|
Apart from brand drugs containing the same ingredient, some generics have also been filed for Fluticasone Propionate; Salmeterol Xinafoate, Advair Diskus 500/50's active ingredient. Check the complete list of approved generic manufacturers for Advair Diskus 500/50
About Advair Diskus 500/50
Advair Diskus 500/50 is a drug owned by Glaxo Group Ltd England Dba Glaxosmithkline. It is used for managing symptoms associated with a specific medical condition. Advair Diskus 500/50 uses Fluticasone Propionate; Salmeterol Xinafoate as an active ingredient. Advair Diskus 500/50 was launched by Glaxo Grp Ltd in 2000.
Approval Date:
Advair Diskus 500/50 was approved by FDA for market use on 24 August, 2000.
Active Ingredient:
Advair Diskus 500/50 uses Fluticasone Propionate; Salmeterol Xinafoate as the active ingredient. Check out other Drugs and Companies using Fluticasone Propionate; Salmeterol Xinafoate ingredient
Treatment:
Advair Diskus 500/50 is used for managing symptoms associated with a specific medical condition.
Dosage:
Advair Diskus 500/50 is available in powder form for inhalation use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 0.5MG/INH;EQ 0.05MG BASE/INH | POWDER | Prescription | INHALATION |